EndoTrap® Removes Endotoxin from Phage Cocktail Used Against Drug-Resistant P. aeruginosa Infection

by Ian Fenna
Image of a vial containing BFC1 bacteriophage cocktail for clinical trial use against antibiotic-resistant infections. Image by Merabishvili et al.

Publication

EndoTrap® Endotoxin Removal Products were cited in a 2022 Nature article by Van Nieuwenhuyse, Brieuc et al., “Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler.”

In a case where a toddler had an extensively drug-resistant Pseudomonas aeruginosa sepsis following liver transplantation, BFC1 bacteriophage cocktail was used in combination therapy with antibiotics for 86 days.

The BFC1 bacteriophage cocktail is produced by the Queen Astrid Military Hospital (QAMH) in Brussels. It contains one Staphylococcus aureus phage (ISP) and two P. aeruginosa phages (PNM and 14-1). EndoTrap® affinity chromatography products were used to remove endotoxin (LPS) from the bacteriophage preparation, which was then certified by the Belgian Institute for Public Health (Sciensano) to contain less than 5 EU/mL of endotoxins.

Following phage-antibiotic combination therapy, the P. aeruginosa infection cleared from the bloodstream, which allowed the patient to receive a liver re-transplantation. Two years after re-transplantation, the patient remains in good health and free of new infection.

Citation

This content has been adapted from the paper below. You can find the entire paper via the link:

Van Nieuwenhuyse, B., Van der Linden, D., Chatzis, O., Lood, C., Wagemans, J., Lavigne, R., Schroven, K., Paeshuyse, J., de Magnée, C., Sokal, E., Stéphenne, X., Scheers, I., Rodriguez-Villalobos, H., Djebara, S., Merabishvili, M., Soentjens, P., & Pirnay, J. P. (2022). Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nature communications, 13(1), 5725.
https://doi.org/10.1038/s41467-022-33294-w

 

Product Spotlight

EndoTrap® HD is an affinity chromatography resin based on a bacteriophage-derived protein which binds to endotoxins with high affinity and specificity. It removes endotoxins (lipopolysaccharides/LPS) from aqueous solutions of a wide range of samples such as bacteriophages, proteins, antibodies, vaccines, nucleic acids, buffers and cell extracts with excellent sample recovery rate.

EndoTrap® is an affinity matrix intended for removal of lipopolysaccharide (LPS) from biological samples in aqueous solutions such as proteins, antibodies, cell extracts and nucleic acids

 

Ilex Life Sciences LLC is an official distributor of LIONEX GmbH products. To learn more about EndoTrap® HD, please visit our EndoTrap® HD product page.

Back to Blog